Heart medicine ivabradine gets fast-track status by FDA.

Forbes (4/17) reported Amgen disclosed yesterday that the FDA has given fast-track status to “its new chronic heart failure drug ivabradine.” The medicine has been sold for several years in Europe “by Servier under the brand name of Procoralan.” Amgen has noted that it plans to submit the application for the agency’s approval “in the second half of this year,” Forbes added.